
Topic
Coverage Access
Formulary tiers, utilization management, patient support, and the access layer GoodRx and drug labels do not explain.

Policy· August 30, 2026 · 17 min read

Specialty· August 30, 2026 · 23 min read
Libre Duo's Dual Glucose-Ketone De Novo Is Not a Medicare CGM Coverage Decision

Approvals· August 30, 2026 · 16 min read
Mounjaro's CV Claim Is Noninferiority vs Trulicity, Not Placebo Superiority
By Ran Chen#GLP-1#GIP/GLP-1#Diabetes and Obesity

Evidence· August 29, 2026 · 23 min read
Treatment-Regimen Estimands in FDA Labels: Answering the Real Coverage Question
By Ran Chen#Clinical Evidence#Clinical Trials#FDA

Approvals· August 29, 2026 · 15 min read
Lisraya's DM Label: Boxed-Warning 30 mg Tablet, Table 3 Split, Unapproved 15 mg
By Ran Chen#FDA Approval#JAK Inhibitor#Dermatology

Approvals· August 29, 2026 · 24 min read
Mimrylo for PV Erythrocytosis: 76.9% Week 20-32 Response and Platelet Rises
By Ran Chen#FDA Approval#Hematology#Coverage Access

Approvals· August 29, 2026 · 17 min read
Rasonque's Pancreatic Label Needs No RAS Test: 2L Data Does Not Write 1L Access
By Ran Chen#FDA Approval#Oncology#Coverage Access

Approvals· August 27, 2026 · 20 min read
Imaavy's wAIHA Approval Is a Steroid-Gated, q4w Indication: J9256 Does Not Auto-Cover It

Approvals· August 27, 2026 · 18 min read
Tivicay PD's Neonatal Expansion: Term, 2 kg Floor; Tablets Do Not Substitute
By Ran Chen#FDA Approval#HIV#Infectious Disease

Policy· August 24, 2026 · 20 min read
HHS Vaccine-Category RFI: What SCDM Means for ACA and VFC Coverage Clocks
By Ran Chen#Policy#Coverage Access#Payer Policy